Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jun 19;11(5):513–522. doi: 10.1111/cts.12569

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 The Authors. Clinical and Translational Science published by Wiley Periodicals, Inc. on behalf of Society for Clinical and Translational Science and Association for Patient Oriented Research

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Effect of oral dutasteride on oral testosterone (T) metabolism in vivo and in vitro. (a) Pharmacokinetic profile of testosterone and its primary (testosterone glucuronide (TG), dihydrotestosterone (DHT), and androstenedione (AED)) and secondary (androsterone (A), androsterone glucuronide (AG), etiocholanolone (Etio), and etiocholanolone glucuronide (EtioG)) metabolites after single oral dose (200 mg) of testosterone with (dotted line) and without (solid line) dutasteride co‐administration (n = 7). Dots represent mean plasma concentration at individual sampling time points and bars represent SE. (b) Effect of co‐administered dutasteride on the levels of testosterone metabolites in the pooled serum (n = 7) indicating fold change at T200 and T800. (c) Effect of dutasteride cotreatment on the levels of DHT, A, and AG in human hepatocyte culture. Data for panels b and c were analyzed using Paired t test, **P value < 0.01, ***P value < 0.001.